🔎 Trials Near Me

Domov › Metastatická rakovina › Kentucky › Lexington

Klinické štúdie Metastatická rakovina v meste Lexington, KY

11 štúdií pre Metastatická rakovina hľadá účastníkov v zariadeniach v meste Lexington a okolí (do cca 30 míľ). Otvorte štúdiu a zistite, kto sa môže zapojiť a ako kontaktovať tím.

Oficiálny text štúdie (anglicky)

Hľadáte účastníkov do štúdie? Zvýraznite ju na začiatku tejto stránky – $99 na 30 dní →

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Prebieha náborFáza 2
  • CommonSpirit Saint Joseph Medical Center - East Lexington, Lexington
  • University of Kentucky/Markey Cancer Center, Lexington
Všetky vekové kategórie · Všetky pohlavia · Aktualizované 5. 10. 2026 · NCT05564377

Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

Prebieha náborFáza 1
  • University of Kentucky/Markey Cancer Center, Lexington
Vek 18 a viac · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT05372614

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

Prebieha náborFáza 2/3
  • University of Kentucky Markey Cancer Center, Lexington
Vek 18 a viac · Všetky pohlavia · Aktualizované 29. 9. 2026 · NCT06943755

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

Prebieha náborFáza 3
  • Baptist Health Lexington, Lexington
  • Baptist Health Richmond, Lexington
  • Baptist Health Hamburg, Lexington
  • a 3 ďalších
Vek 18 a viac · Všetky pohlavia · Aktualizované 28. 9. 2026 · NCT07222800

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

Prebieha náborFáza 2/3
  • University of Kentucky Research Foundation, Lexington
  • University of Kentucky Healthcare - Markey Cancer Center, Lexington
  • University of Kentucky Medical Center, Lexington
  • a 1 ďalších
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06989437

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

Prebieha náborFáza 3
  • Baptist Health Lexington, Lexington
Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT07213804

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Prebieha náborFáza 3
  • CHI Saint Joseph Cancer Center - East, Lexington
  • University of Kentucky Chandler Medical Center, Lexington
Vek 18 a viac · Všetky pohlavia · Aktualizované 8. 9. 2026 · NCT06119581

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

Prebieha náborFáza 2
  • University of Kentucky/Markey Cancer Center, Lexington
Vek 18 a viac · Všetky pohlavia · Aktualizované 4. 9. 2026 · NCT06311214

A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

Prebieha náborFáza 1/2
  • Crinetics Study Site, Lexington
Vek 18 a viac · Všetky pohlavia · Aktualizované 31. 7. 2026 · NCT07129252

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Prebieha náborFáza 1
  • UK Markey Cancer Center, Lexington
Vek 18 a viac · Všetky pohlavia · Aktualizované 11. 6. 2026 · NCT05283330

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

Prebieha náborFáza 1
  • University of Kentucky Markey Cancer Center, Lexington
Vek 18 a viac · Všetky pohlavia · Aktualizované 13. 2. 2026 · NCT06778863

Štúdie Metastatická rakovina v iných mestách

Iné štúdie v Lexington

Z ClinicalTrials.gov, dáta načítané 6. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.